Home-HF: Evaluation of Patients With Heart Failure Using Home Telemonitoring

This study has been completed.

Sponsor:

Collaborator:

Honeywell HomMed

Information provided by (Responsible Party):

Imperial College London

ClinicalTrials.gov Identifier:

NCT00312884

First received: April 7, 2006

Last updated: April 26, 2016

Last verified: November 2007

History of Changes

Results First Received: October 27, 2015

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Heart Failure
Intervention:	Device: HomMed Telemonitoring System

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Intervention Arm	Recieved home telemonitoring daily HomMed Telemonitoring System: The HomeMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
Usual Care	Received usual hospital care with no Telemonitoring

Participant Flow: Overall Study

	Intervention Arm	Usual Care
STARTED	91	91
COMPLETED	74	79
NOT COMPLETED	17	12

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Usual Care	Recieved usual follow-up care
Intervention Arm	Received daily home monitoring
Total	Total of all reporting groups

Baseline Measures

	Usual Care	Intervention Arm	Total
Overall Participants Analyzed [Units: Participants]	91	91	182

Age [Units: Participants]
<=18 years	0	0	0
Between 18 and 65 years	30	30	60
>=65 years	61	61	122

Age [Units: Years] Mean (Standard Deviation)	72 (10.4)	70 (12.8)	71 (11)

Gender [Units: Participants]
Female	32	29	61
Male	59	62	121

Region of Enrollment [Units: Participants]
United Kingdom	91	91	182

Outcome Measures

Show All Outcome Measures

1. Primary:

Days Alive and Outside of Hospital [ Time Frame: From date of randomisation for 180 days ]

Show Outcome Measure 1

2. Primary:

Patients Hospitalised (All Cause) [ Time Frame: From randomisation date to 180 days ]

Show Outcome Measure 2

3. Primary:

Number of Days Spent in Hospital [ Time Frame: From randomisation date for 180 days ]

Show Outcome Measure 3

4. Primary:

Number of Hospitalisations (All Cause) [ Time Frame: from randomisation for 180 days ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Professor Cowie
Organization: Imperial College london
phone: 0207 349 7716
e-mail: m.cowie@imperial.ac.uk

Responsible Party:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00312884 History of Changes
Other Study ID Numbers:	2006EP001B 05/Q0411/112
Study First Received:	April 7, 2006
Results First Received:	October 27, 2015
Last Updated:	April 26, 2016

To Top